From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

A Promising Pocket Pharma Like This Could Pluck Perky Pickings. But You Need Nerve.

By Malcolm Stacey | Wednesday 11 October 2017


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Hello, Share Choosers. As we've often said on this glittering website, investing in small drugs companies is fraught with peril. Cures and remedies take ages to develop, and then you have to steer them through a punishing licence minefield. I’m a great believer, though, in this kind of punt, as the world becomes older and less healthy. And investment in the right pharma could reap big rewards for shareholders, but mainly the sick among us. Today’s suggestion seems a more promising pocket pharma than most.


Filed under:



That Was the Week that Was

 

ICON

Iconic Labs – its alive!

Wednesday »

Bearcast

Tom Winnifrith Bearcast: Family tales

 

SHG

Shanta Gold – a recovery BUY!

 

MUSH

Oscillate RTO – madness

 

MOON

Surely Moonpig is a short at 171p?

 

Atomic

Video: The Road to an Energy Crisis

 

Bear

Beyond Meat is Beyond Redemption.

Friday »

Bearcast

Tom Winnifrith bearcast: Madness!

 

RRR

The Andrew Bell defence at Red Rock